Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting

Dose escalation of neratinib lowers the frequency of severe diarrhea and improves overall tolerability in patients with HER2-positive early stage breast cancer

Find Out More

Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting

Neratinib efficacy evidenced in patients with EGFR exon 18-mutant non-small cell lung cancer and CNS involvement

Find Out More

Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting

Results show improved outcomes in overall survival in patients with HER2-positive early stage breast cancer who received &ge= 11 months of treatment with neratinib

Find Out More

https://www.businesswire.com/news/home/20210105005759/en/Puma-Biotechnology-to-Present-at-the-J.P.-Morgan-Healthcare-Conference

https://pumabiotechnology.com/pr20201211_NALA.html

https://pumabiotechnology.com/pr20201209_ExteNET.html

https://pumabiotechnology.com/pr20201209_SUMMIT.html

https://pumabiotechnology.com/pr20201117.html

https://pumabiotechnology.com/pr20201105_SUMMIT.html

https://pumabiotechnology.com/docs/101520_NCCNORP_Puma_Neratinib.pdf